Four phase 1 trials to evaluate the safety and pharmacokinetic profile of single and repeated dosing of SCO-101 in adult male and female volunteers

Research output: Contribution to journalJournal articleResearchpeer-review

Documents

  • bcpt.13466

    Final published version, 537 KB, PDF document

SCO-101 (Endovion) was discontinued 20 years ago as a new drug under development against sickle cell anaemia. Data from the phase 1 studies remained unpublished. New data indicate that SCO-101 might be efficacious as add-on therapy in cancer. Thus, we report the results from the four phase 1 trials performed between 2001 and 2002. Adult volunteers received SCO-101 or placebo in four independent trials. Adverse events were recorded, and SCO-101 was determined for pharmacokinetic analysis. Ninety-two volunteers completed the trials. The most remarkable adverse effect was a transient and dose-dependent increase in unconjugated bilirubin. Plasma SCO-101 elimination was approximately log linear, with apparent oral clearances of between 315 and 2103 mL/h for single doses, and between 121 and 2433 mL/h at steady state following oral administration. There was a marked decrease in clearance with increasing dose, and for repeated dose versus single dose.T(max)was greater, andC(max)and AUC(infinity)were lower in the fed state compared to the fasted state. Exposure was equivalent in males and females and for African Americans and Caucasians. In conclusion, SCO-101 appears to be a safe drug with a predictable PK profile. Its efficacy as add-on to standard anticancer drugs has yet to be defined.

Original languageEnglish
JournalBasic & Clinical Pharmacology & Toxicology
Volume127
Issue number4
Pages (from-to)329-337
ISSN1742-7835
DOIs
Publication statusPublished - 2020

    Research areas

  • cancer chemotherapy, development, discovery and development, drug, drug discovery, drug discovery and development, pharmacokinetics, safety evaluation, safety pharmacology, RESISTANCE, CANCER, CELLS

ID: 248332947